

#### **▶ SHIELDS OUTCOMES**

# Oncology

Cancer, a genetic disease in which some of the body's cells grow uncontrollably and spread to other parts of the body, is caused by changes to genes that control the way our cells function.1

#### **TREATMENT**

With over 100 types of cancer, the treatment varies depending on the type and severity. The goals of cancer treatment include eradicating known tumors, preventing the recurrence or spread of the primary cancer, and relieving symptoms.2



## **3 Common Barriers to Oncology Treatment**

- **FINANCIAL BURDEN** Patients with high out-of-pocket costs are more likely to discontinue
  - **ADVERSE EFFECTS** OF MEDICATIONS Many treatment options have harmful side effects cancer therapy. 3,4 and require frequent monitoring.



One study found patients with out-of-pocket costs between \$100 and \$500 were associated with a **32%** therapy abandonment rate.5



Adverse events were cited as the reason for 39% of early discontinuations in a study of patients on oral oncology agents at a national specialty pharmacy. 6

## **SOCIAL SUPPORT**

As patients navigate their cancer journey, having a solid support system is correlated with better outcomes.



Lack of adequate social support for oncology patients is associated with higher mortality in certain types of cancer as compared to patients with high levels of social support.7

## **How Shields Helps**

- Shields understands the financial complexities that oncology patients often face, which is why our team of liaisons work with patients to help them afford their treatment through financial assistance programs.
- Through our high-touch care model, Shields pharmacists provide patients with customized care focused on identifying pre-existing drug-related issues and mitigating treatment-related side effects, helping keep patients on track.
- Our Shields clinical team aims to enhance patients' quality of life by providing access to additional social support networks through high engagement and collaboration with the patient and caregiver.

### **SHIELDS OUTCOMES**

## Oncology



OUR PROVEN CARE MODEL BREAKS DOWN BARRIERS TO CARE TO OPTIMIZE PATIENT OUTCOMES.

Shields Health Solutions' dedicated clinical team of pharmacists, liaisons and patient support advocates, engage patients and their families to help educate, coordinate care and ensure patients receive specialty medication without significant delays. Our integrated care model lowers the cost of care by preventing unnecessary ER, hospital and physician appointments.<sup>8</sup>

#### **ENGAGE**

Our clinical team engage with patients at the clinic and through telehealth appointments.

#### **INTERVENE**

Clinical pharmacists intervene to improve the patient's care plan when drug interactions, related side effects, barriers to adherence or other obstacles are identified.

#### COORDINATE

Liaisons investigate patient benefits, complete prior authorizations and identify financial assistance, minimizing barriers to optimal therapy.

#### **ENHANCE**

Through clinical pharmacist interventions, we can enhance patient care by providing support, education, and optimizing therapy when challenges arise, and treatment goals are not being met.

#### **RENEW**


Ongoing interactions beyond refills; proactively identify opportunities to improve patient care and outcomes at each touchpoint.

#### FAs/PAs Completed & Hours Saved (YTD)

Clinical staff utilizes their time to focus on patient care.

#### **Average Copay**

Patients can access and afford treatment.



<sup>1.</sup> National Cancer Institute https://www.cancer.gov/about-cancer/understanding/what-is-cancer Updated May 5, 2021. Accessed May 14, 2021

National Cancer Institute. Seer Training Modules https://training.seer.cancer.gov/treatment/ Accessed Oct 15th. 2021.

<sup>3.</sup> Kaisaeng N, et al. J Manag Care Spec Pharm 2014;20(7):669-75

<sup>4.</sup> Streeter SB, et al. J Oncol Pract 2011;7(3 Supple):46s-51s

<sup>5.</sup> Doshi JA, et al. J Clin Oncol. 2018;36(5):476-82

<sup>6.</sup> Deutsch S, et al. J of Oncology Pharmacy Practice 2016;22(1):68-75

<sup>7.</sup> Kroenke C, et al. Cancer 2020;126:1766-1775

<sup>8.</sup> Fasching D, Donovan J, Smullen K, Ditch K, Smith B. Improved Oncology Total Medical Expense Associated with the use of Integrated Health System Specialty Pharmacy Care Model. Poster presented at ASHP;
July 14-16, 2021; Virtual Meeting.